Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Cencora (COR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Cencora is a member of our Medical group, which includes 1002 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 (Buy).Over the past 90 days, the Zacks Consensus Estimate for COR's full-year earnings has moved 0.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the most recent data, COR has returned 27.6% so far this year. Meanwhile, stocks in the Medical group have lost about 5.6% on average. This means that Cencora is outperforming the sector as a whole this year.Intensity Therapeutics Inc. (INTS) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 5.1%.Over the past three months, Intensity Therapeutics Inc.'s consensus EPS estimate for the current year has increased 9.6%. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Cencora belongs to the Medical Services industry, which includes 58 individual stocks and currently sits at #86 in the Zacks Industry Rank. This group has lost an average of 3% so far this year, so COR is performing better in this area.In contrast, Intensity Therapeutics Inc. falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 508 stocks and is ranked #72. Since the beginning of the year, the industry has moved -7.7%.Investors with an interest in Medical stocks should continue to track Cencora and Intensity Therapeutics Inc. These stocks will be looking to continue their solid performance.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR): Free Stock Analysis Report Intensity Therapeutics Inc. (INTS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks